Cytokinetics Inc (CYTK)
60.39
-0.21
(-0.35%)
USD |
NASDAQ |
May 21, 14:33
Cytokinetics SG&A Expense (Quarterly): 45.50M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 45.50M |
December 31, 2023 | 44.11M |
September 30, 2023 | 40.11M |
June 30, 2023 | 39.72M |
March 31, 2023 | 49.66M |
December 31, 2022 | 53.97M |
September 30, 2022 | 48.22M |
June 30, 2022 | 42.72M |
March 31, 2022 | 33.07M |
December 31, 2021 | 33.81M |
September 30, 2021 | 26.20M |
June 30, 2021 | 21.20M |
March 31, 2021 | 15.60M |
December 31, 2020 | 13.91M |
September 30, 2020 | 12.30M |
June 30, 2020 | 14.16M |
March 31, 2020 | 12.45M |
December 31, 2019 | 10.58M |
September 30, 2019 | 9.753M |
June 30, 2019 | 9.836M |
March 31, 2019 | 9.437M |
December 31, 2018 | 7.558M |
September 30, 2018 | 7.164M |
June 30, 2018 | 8.046M |
March 31, 2018 | 9.264M |
Date | Value |
---|---|
December 31, 2017 | 10.26M |
September 30, 2017 | 9.657M |
June 30, 2017 | 8.438M |
March 31, 2017 | 8.115M |
December 31, 2016 | 6.674M |
September 30, 2016 | 7.217M |
June 30, 2016 | 7.09M |
March 31, 2016 | 6.841M |
December 31, 2015 | 5.529M |
September 30, 2015 | 5.276M |
June 30, 2015 | 4.495M |
March 31, 2015 | 4.367M |
December 31, 2014 | 4.558M |
September 30, 2014 | 3.993M |
June 30, 2014 | 4.458M |
March 31, 2014 | 4.259M |
December 31, 2013 | 4.093M |
September 30, 2013 | 3.635M |
June 30, 2013 | 3.73M |
March 31, 2013 | 3.634M |
December 31, 2012 | 3.815M |
September 30, 2012 | 2.991M |
June 30, 2012 | 2.568M |
March 31, 2012 | 3.056M |
December 31, 2011 | 2.863M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
9.753M
Minimum
Sep 2019
53.97M
Maximum
Dec 2022
28.84M
Average
29.64M
Median
SG&A Expense (Quarterly) Benchmarks
Amgen Inc | 1.808B |
Johnson & Johnson | 5.057B |
Viking Therapeutics Inc | 9.97M |
Eli Lilly and Co | 1.836B |
Madrigal Pharmaceuticals Inc | 80.80M |